Andrew J. Hirsh
Parion Sciences Inc.
2525 Meridian Pkwy.
Suite 260
Durham
USA
Name/email consistency: high
- Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. Hirsh, A.J., Zhang, J., Zamurs, A., Fleegle, J., Thelin, W.R., Caldwell, R.A., Sabater, J.R., Abraham, W.M., Donowitz, M., Cha, B., Johnson, K.B., St George, J.A., Johnson, M.R., Boucher, R.C. J. Pharmacol. Exp. Ther. (2008)
- Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. Hirsh, A.J., Molino, B.F., Zhang, J., Astakhova, N., Geiss, W.B., Sargent, B.J., Swenson, B.D., Usyatinsky, A., Wyle, M.J., Boucher, R.C., Smith, R.T., Zamurs, A., Johnson, M.R. J. Med. Chem. (2006)
- Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. Hirsh, A.J., Sabater, J.R., Zamurs, A., Smith, R.T., Paradiso, A.M., Hopkins, S., Abraham, W.M., Boucher, R.C. J. Pharmacol. Exp. Ther. (2004)
- Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Hirsh, A.J. Adv. Drug Deliv. Rev. (2002)
